The role of nuclear medicine in the diagnosis of cancer of unknown origin

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 2, 2004, Pages 164-173

  Demir, H ^a   Berk, F ^a   Raderer, M ^b   Plowman, P N ^c   Lassen, U ^d   Daugaard, G ^d   Clausen, M ^e   Bohuslavizki, K H ^e   Peters, M ^f   Harmer, C ^g   Malamitsi, J ^h   Aktolun, C ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY OF ATHENS   (Greece)

Author keywords

Fluorodeoxyglucose F18; Neoplasms, radionuclide imaging; Nuclear medicine; Tomography emission computed

Indexed keywords

ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 67; PLATINUM; TECHNETIUM 99M; TUMOR MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HUMAN; IDIOPATHIC DISEASE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NUCLEAR MEDICINE; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOASSAY; SURVIVAL RATE; THYROID SCINTISCANNING; TUMOR BIOPSY; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING; BLOOD; BONE; BONE TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LYMPH NODE METASTASIS; NEOPLASM; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BONE AND BONES; BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 4544252303     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Nissenblatt MJ Carcinoma with unknown primary tumour. South Med J 1981;74:1497-502.
2. Leonard JR, Nystrom J. Diagnostic evaluation of patients with carcinoma of unknown primary tumour site. Semin Oncol 1993;20: 244-50.
3. Didolker MS, Fanous N, Elias EG, Moore RH. Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 1997;186:625-30.
4. Nystrom JS, Weiner JM, Wolf RM, Bateman JR, Viola MV. Identifying the primary site in metastatic cancer of unknown origin: inadequacy of roentgenographic procedure. JAMA 1979;241:381-3.
5. Krementz ET, Cerise EJ, Foster DS, Morgan LR Jr. Metastases of undetermined source. Curr Probl Cancer 1979;4:4-37.
6. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG. Treatment of the patients with adenocarcinoma of unknown origin. Cancer 1972;30:1469-72.
7. Krementz ET, Cerise EJ, Ciaravella JM. Metastases of undetermined source, Ca Cancer J Clin 1977;27:289-300.
8. Nystrom JS, Weiner JM, Heffielfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53-8.
9. Sugarbaker EV. Cancer metastasis: a product of tumour-host interactions. Curr Probl Cancer 1979;3:1-59.
10. Chorost MI, McKinley B, Tschoi M, Glosh BC. The management of the unkwon primary. J Am Coll Surg 2001;193:666-77.
11. Jones AS, Phillips DE, Helliwell TR, Ronald TR, Ronald TJ. Occult metastases in head and neck squamous carcinoma. Eur Arch Otorhinolarynol 1993;250:446-9.
12. Schipper JH, Schrader M, Arweiler D, Müller S, Sciuk J. Value of positron emission tomography in patients with cervical metastases but unknown primary tumor site (in German). HNO 1996;44:254-7.
13. Snee PM, Vyramuthu N. Metastatic carcinoma from unknown primary site: the experience of a large oncology centre. Br J Radiol 1985; 58:1091-5.
14. Snow GB, Patel P, Leemans CR, Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. Arch Otorhinolarynol 1992;249:187-94.
15. Greco FA, Hainsworth, JD. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site. Semin Oncol 1989;16:116-22.
16. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2001;12:1057-8.
17. Greco FA, Hainsworth, JD. Cancer of unknown primary site. In: Devita VT, Hellman S, Rosengberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997.p. 2423-43.
18. van der Gaast A, Verweij J, Planting AS, Stoter G, Henzen-Logmans SC. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of uknown primary. J Cancer Res Clin Oncol 1996;122:181-5.
19. Kagan AR, Steckel RJ. The Limited role of radiologic imaging in patients with unknown tumour primary. Semin Oncol 1991;18: 170-3.
20. Golomb HM, De Meester TR. Lung cancer: a combined modality approach to staging and therapy. CA Cancer J Clin 1979;29:258-75.
21. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997;8 Suppl 1:53-6.
22. Front D, Israel O. The role of Ga-67 scintigraphy invaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60-71.
23. Biersack HJ, Briele B, Hotze AL, Oehr P, Qian L, Mekkawy MA et al. The role of nuclear medicine in oncology. Ann Nucl Med 1992;6:131-6.
24. Front D, Israel O, Epelbaum R, Ben Haim S, Sapir EE, Jerushalmi J et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990;175:515-9.
25. Drossman SR, Schiff RG, Kronfeld GD, McNamara J, Leonidas JC. Lymphoma of the mediastinum and neck: evaluation with Ga-67 imaging and CT correlation. Radiology 1990;174:171-5.
26. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-15.
27. Delbeke D. Oncological applications of FDG PET imaging: brain tumours, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999;40:591-603.
28. Bohuslavizki KH, Klutmann S, Kröger S, Sonnemann U, Buchert R, Werner JA et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-22.
29. Lassen U, Daugaard G, Eigteved A, Damgaard K, Friberg L. 18-FDG Whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35:1076-82.
30. Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W. Localised disease in cancer of uknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605-9.
31. Lonneux M, Reffad A. Metastases from unknown primary tumor. PET-FDG as initial diagnostic procedure? Clin Positron Imaging 2000;3:137-41.
32. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-9.
33. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171: 21-6.
34. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
35. Yonekura Y, Benua RS, Brill AB, Som P, Yeh SID, Kemeny NE et al. increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982;23: 1133-7.
36. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54:248-52.
37. Bombardieri E, Carrio I, Gonzalez P, Serafini A, Turner JH, Virgiolini I et al. (Task Group of Oncology). Current applications and perspectives of diagnostic nuclear medicine in oncology. Int J Oncol 1999;14:877-90.
38. AAssar OS, Fiscbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumours. Radiology 1999;210:177-81.
39. Weber A, Schmoz S, Bootz F. CUP (carcinoma of unknown primary) syndrome in head and neck: clinic, diagnostic, and therapy. Onkologie 2001;24:38-43.
40. 18F)-Fluoro-2deoxy-D-Glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123:294-301.
41. Bohuslavizki KH, Klutman S, Sonnemann U, Thoms J, Kroger S, Werner JA et al. F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region. Laryngorhinootologie 1999;78:445-9.
42. Paulus P, Sambon A, Vivegnis D, Hustinx R, Moreau P, Collignon J. 18-FDG PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathologic correlation in 38 patients. Laryngoscope 1998;108:1578-83.
43. Mukherji SK, Drane WE, Mancuso AA, Parsons JT, Mendenhall WM, Stinger S. Occult primary tumors of the head and neck: detection with 2-[F-18] fluora-2-deoxy-D-glucose SPECT. Radiology 1996;199:761-6.
44. Perie S, Talbot J, Monceaux G, Grahek D, Kerrou K, Montravers F et al. Use of a coincidence γ camera to detect primary tumour with F-18 FDG in cervical lymph node metastases from an unknown origin. Ann Otol Rhinol Laryngol 2000;109:755-60.
45. Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T et al. Feasibility of fluorodeoxyglucose dual-head γ camera coincidence imaging in the evaluation of lung cancer: comparison with FDG SPECT. J Nucl Med 1999;40:566-73.
46. Inoue T, Oriuchi N, Koyama K, Ichikawa A, Tomiyoshi K, Sato N et al. Usefulness of dual-head coincidence γ camera with thick NaI crystals for nuclear oncology: comparison with dedicated PET camera and conventional γ camera with thin NaI crystals. Ann Nucl Med 2001;15:141-8.
47. Delbeke D, Sandler MP. The role of hybrid cameras in oncology. Semin Nucl Med 2000;30:268-80.
48. Landoni C, Gianolli L, Lucignani G, Magnani P, Savi A, Travaini L et al. Comparison of dual-head coincidence PET versus ring PET in tumor patients. J Nucl Med 1999;40:1617-22.
49. Ruddon RW, Norton SE. Use of biological markers in the diagnosis of cancers of unknown primary tumor. Semin Oncol 1993;3:251-60.
50. Sergeni E, Bombardieri E. Tumor markers in oncology. In: Aktolun C, Tauxe WN, editors. Nuclear oncology. Berlin, Heidelberg: Springer-Verlag; 1999.p.415-32.
51. Daugaard G, Hansen HH. Management of carcinoma of unknown primary site (CUP), any changes? Ann Oncol 2001;12:431-2.
52. Saghatchian M, Fizazi K, Borel C, Ducreux M, Ruffie P, Le Chevalier T et al. Carcinoma of an unkwon primary site: a chemotherapy strategy based on histological differentiation. Results of a prospective study. Ann Oncol 2001;12:535-40.